Scientists discover a technology that eliminates “vicious cancer”

glioblastoma The most common and aggressive brain tumor in adults, it can also affect the spinal cord; It grows and spreads rapidly, and has a great ability to resist treatment.

While treatments such as surgery, radiation and chemotherapy can help relieve symptoms for a few months, in most cases the cancer cells grow again after treatment, and the cancer comes back.

Here, the researchers see the need to uproot the tumor so that it does not return again, which is what they worked on in the study recently published in the journal Cell Reports.

Tumor roots

Of all cancer cells, the researchers say, some act as stem cells that reproduce and sustain cancer, just like normal stem cells that regenerate and maintain our organs and tissues. By targeting the way the cells function, they’ve discovered a new way to disrupt the production of new tumors.

For his part, says Arizu Jahani Asel, assistant professor of medicine at the University of McGill: "What we found was really amazing to us, after we inhibited the protein galectin1, the brain tumors simply didn’t grow for several months.".

Duration: "To improve a patient’s response to treatment, we must exploit newly identified weaknesses in CSCs."

The researchers discovered that a protein called galectin1 interacts with another protein called HOXA5 to control the genetic programs that drive the behavior of cancer stem cells. By suppressing galectin1 in preclinical models, they found a significant improvement in the tumor’s response to radiotherapy, extending the animal’s lifespan.

The researchers also analyzed patient databases and found that glioblastoma patients with reduced expression of the proteins galectin1 and HOXA5 had a better prognosis, as these proteins together with another protein called STAT3 activate mechanisms that promote a particularly aggressive type of Glioblastoma.

The way to new treatments

This discovery sheds light on the mechanisms that regulate cancer stem cells, and the results provide evidence that targeting galectin1, in parallel with radiotherapy, could pave the way for future clinical trials for the treatment of glioblastoma tumors.

The next step is to compare the efficacy of different approaches to suppress HOXA5 and galectin1 in the brain, with advances in gene therapy using CRISPR technology to reprogram genes into stem cells.

“>

ويعتبر glioblastoma The most common and aggressive brain tumor in adults, it can also affect the spinal cord; It grows and spreads rapidly, and has a great ability to resist treatment.

While treatments such as surgery, radiation and chemotherapy can help relieve symptoms for a few months, in most cases the cancer cells grow again after treatment, and the cancer comes back.

Here, the researchers see the need to uproot the tumor so that it does not return again, which is what they worked on in the study recently published in the journal Cell Reports.

Tumor roots

Of all cancer cells, the researchers say, some act as stem cells that reproduce and sustain cancer, just like normal stem cells that regenerate and maintain our organs and tissues. By targeting the way the cells function, they’ve discovered a new way to disrupt the production of new tumors.

For his part, says Arizu Jahani Asel, assistant professor of medicine at the University of McGill: “What we found was really amazing to us, after we inhibited the protein galectin1, the brain tumors simply didn’t grow for several months.”

“To improve a patient’s response to treatment, we must exploit the newly identified weaknesses in CSCs,” he adds.

The researchers discovered that a protein called galectin1 interacts with another protein called HOXA5 to control the genetic programs that drive the behavior of cancer stem cells. By suppressing galectin1 in preclinical models, they found a significant improvement in the tumor’s response to radiotherapy, extending the animal’s lifespan.

The researchers also analyzed patient databases and found that glioblastoma patients with reduced expression of the proteins galectin1 and HOXA5 had a better prognosis, as these proteins together with another protein called STAT3 activate mechanisms that promote a particularly aggressive type of Glioblastoma.

The way to new treatments

This discovery sheds light on the mechanisms that regulate cancer stem cells, and the results provide evidence that targeting galectin1, in parallel with radiotherapy, could pave the way for future clinical trials for the treatment of glioblastoma tumors.

The next step is to compare the efficacy of different approaches to suppress HOXA5 and galectin1 in the brain, with advances in gene therapy using CRISPR technology to reprogram genes into stem cells.